Ovarian cancer (ovarian cancer) accounts for 2.4% ~ 6.5% of the common malignant tumors in women, and ranks the third among the cancers of the female reproductive system, secondary to cervical cancer and uterine body cancer.In recent years, due to the prevention and treatment of cervical cancer and uterine body cancer, some achievements have been made, while the prevention and treatment of ovarian cancer is relatively small.So ovarian cancer is the leading cause of death among cancers of the reproductive system in women.
This report contains market size and forecasts of Therapies and Diagnostics for Ovarian Cancer in Global, including the following market information:
Global Therapies and Diagnostics for Ovarian Cancer Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Therapies and Diagnostics for Ovarian Cancer market was valued at 2055 million in 2021 and is projected to reach US$ 2673 million by 2028, at a CAGR of 3.8% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Surgery Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Therapies and Diagnostics for Ovarian Cancer include Astra Zeneca, Clovis Oncology, Myriad, TESARO, AbbVie Inc, Celgene, Janssen Pharmaceuticals, Merck and Novartis AG and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Therapies and Diagnostics for Ovarian Cancer companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Therapies and Diagnostics for Ovarian Cancer Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Therapies and Diagnostics for Ovarian Cancer Market Segment Percentages, by Type, 2021 (%)
Surgery
Radiation Therapy
Drug Treatment
Global Therapies and Diagnostics for Ovarian Cancer Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Therapies and Diagnostics for Ovarian Cancer Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Others
Global Therapies and Diagnostics for Ovarian Cancer Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Therapies and Diagnostics for Ovarian Cancer Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Therapies and Diagnostics for Ovarian Cancer revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Therapies and Diagnostics for Ovarian Cancer revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Astra Zeneca
Clovis Oncology
Myriad
TESARO
AbbVie Inc
Celgene
Janssen Pharmaceuticals
Merck
Novartis AG
Quest Diagnostics Inc